Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
Sign Up to like & getrecommendations! Published in 2018 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2017.10.003
Abstract: Introduction In this phase III, open-label, single-arm, multi-center 12-week study, we evaluated the efficacy and safety of combination therapy with sucroferric oxyhydroxide (PA21) and calcium carbonate for hemodialysis patients with hyperphosphatemia. Methods We enrolled 35… read more here.
Keywords: calcium carbonate; serum phosphorus; oxyhydroxide calcium; sucroferric oxyhydroxide ... See more keywords
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2021.1978973
Abstract: INTRODUCTION Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations. Sucroferric oxyhydroxide is an iron-based phosphate binder… read more here.
Keywords: treatment hyperphosphatemia; hyperphosphatemia; sucroferric oxyhydroxide; safety ... See more keywords
P1411THE EFFICACY AND SAFETY OF THE SUCROFFERRIC OXYHYDXIDE IN HEMODIALYSIS PATIENTS : RESULTS OF A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p1411
Abstract: The treatment of hyperphosphatemia is the main goal in the treatment of mineral and bone disorders in patients with CKD. However, the results of the correction of hyperphosphatemia remain unsatisfactory. This is due to the… read more here.
Keywords: randomized controlled; prospective randomized; sucroferric oxyhydroxide; treatment ... See more keywords
Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
Sign Up to like & getrecommendations! Published in 2022 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfac271
Abstract: ABSTRACT Background Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy… read more here.
Keywords: dialysis patients; dialysis; phosphate binder; calciprotein particles ... See more keywords
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
Sign Up to like & getrecommendations! Published in 2017 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfw242
Abstract: Abstract Background Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphataemia in adult dialysis patients. This post hoc analysis of a randomized, 24-week Phase 3 study and its 28-week extension… read more here.
Keywords: sucroferric oxyhydroxide; related parameters; iron related; iron ... See more keywords
Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients
Sign Up to like & getrecommendations! Published in 2020 at "Blood Purification"
DOI: 10.1159/000505432
Abstract: Introduction: Sucroferric oxyhydroxide (SOH) is an iron-based phosphate binder (PB), and its use has been widely expanded since its initial approval in 2014. Based on the existing data, however, it remains yet unclear whether its… read more here.
Keywords: anemia; sucroferric oxyhydroxide; chronic therapy; iron ... See more keywords